Skip to content
Porphyria News logo
  • About porphyria
    What is porphyria?
    Types
    Causes
    Symptoms
    Diagnosis
  • Treatments
    Approved treatments
  • News
  • Columns
    Hope in Action — Kristen Wheeden
    I’m Not Always Me — Kalyn Shelton
    Archived columns
    • One Thousand Flaming Swords — Claire Richmond
  • Advocacy partners
  • What can we help you find today?

December 6, 2019 News by Mary Chapman

Alnylam Calls for Applicants for ‘Advocacy for Impact’ Grants Helping Rare Disease Communities

In an ongoing effort to help advocacy groups address unmet needs in rare diseases such as porphyria, therapeutic company Alnylam is calling for applicants for its second annual global grants program, called Advocacy for Impact. The $50,000 grants will fund new projects that focus specifically on…

November 22, 2019 News by Marta Figueiredo, PhD

Givosiran Approved by FDA for Treating Adults with Acute Hepatic Porphyria

The U.S. Food and Drug Administration (FDA) has approved Alnylam Pharmaceuticals’ investigational candidate givosiran,  which will be marketed as Givlaari, for the treatment of adults with acute hepatic porphyria (AHP). The approval comes less than four months after the FDA accepted the therapy’s new drug application (NDA) for that…

Recent Posts

  • Case series illustrates challenges in getting diagnosis for AIP women
  • Rare dual diagnosis of lupus and PCT detailed in case report
  • Acute hepatic porphyria carriers need monitoring, study says
  • Feeling the fear that comes with my pohr-fear-ee-uh
  • Woman with HFE mutations gets PCT, sarcoidosis diagnosis
  • COVID-19 triggers AIP attack in woman, 31, case report says
  • Did mental health medications contribute to my AIP attack?
  • Givlaari safe, effective for acute hepatic porphyria patients: Study
  • For Global Porphyria Day, we asked patients to describe their pain


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: info@bionews.com
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.